Identification of a Novel Oxidative Stress-Based Molecular Classification and Treatment Vulnerabilities in WHO Grade 2/3 Meningiomas.

IF 4.1 4区 医学 Q3 ONCOLOGY
Oncology Research Pub Date : 2025-09-26 eCollection Date: 2025-01-01 DOI:10.32604/or.2025.066308
Xiao-Xiao Luo, Bi Peng, Jian-Hua Wang, Guang-Yuan Hu, Xiang-Lin Yuan, Guo-Xian Long
{"title":"Identification of a Novel Oxidative Stress-Based Molecular Classification and Treatment Vulnerabilities in WHO Grade 2/3 Meningiomas.","authors":"Xiao-Xiao Luo, Bi Peng, Jian-Hua Wang, Guang-Yuan Hu, Xiang-Lin Yuan, Guo-Xian Long","doi":"10.32604/or.2025.066308","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The World Health Organization (WHO) grading based on histopathology cannot always accurately predict tumor behavior of meningiomas. To overcome the limitations of the WHO grading, the study aims to propose a novel oxidative stress-based molecular classification for WHO grade 2/3 meningiomas.</p><p><strong>Methods: </strong>Differentially expressed oxidative stress-related genes were analyzed between 86 WHO grade 1 (low grade) meningiomas and 99 grade 2/3 (high grade) meningiomas. An oxidative stress-based molecular classification was developed in high-grade meningiomas through consensus clustering analysis. Immune microenvironment features, responses to immunotherapy and chemotherapy, and targeted drugs were evaluated. Three machine learning models: logistic regression, support vector machine, and random forest, were built for differentiating the classification. Key oxidative stress-related genes were verified in human meningeal cells (HMC) and two meningioma cells (CH-157MN and IOMM-Lee) via reverse transcription quantitative polymerase chain reaction (RT-qPCR) and western blot. After knockdown of Forkhead Box M1 (FOXM1) or Prion Protein (PRNP), cell growth, migration, and reactive oxygen species (ROS) levels were measured through cell counting kit-8 (CCK-8), transwell, and immunofluorescence, respectively.</p><p><strong>Results: </strong>We classified high-grade meningiomas into two oxidative stress-based clusters, termed cluster 1 and cluster 2. Cluster 1 exhibited higher infiltrations of immune and stromal cells and higher expression of classic immune checkpoints: Cluster of Differentiation 86 (CD86), Programmed Cell Death 1 (PDCD1), and Leukocyte-Associated Immunoglobulin-Like Receptor 1 (LAIR1), indicating that cluster 1 meningiomas might respond to immunotherapy. Drug sensitivity was heterogeneous between the two clusters. Three classifiers were established, which could accurately differentiate this molecular classification. FOXM1 and PRNP were experimentally evidenced to be highly expressed in meningioma cells, and their knockdown hindered cell growth and migration and triggered ROS accumulation.</p><p><strong>Conclusion: </strong>In summary, our findings established a novel oxidative stress-based molecular classification and identified potential treatment vulnerabilities in high-grade meningiomas, which might assist personalized clinical management.</p>","PeriodicalId":19537,"journal":{"name":"Oncology Research","volume":"33 10","pages":"2903-2921"},"PeriodicalIF":4.1000,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12494116/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.32604/or.2025.066308","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: The World Health Organization (WHO) grading based on histopathology cannot always accurately predict tumor behavior of meningiomas. To overcome the limitations of the WHO grading, the study aims to propose a novel oxidative stress-based molecular classification for WHO grade 2/3 meningiomas.

Methods: Differentially expressed oxidative stress-related genes were analyzed between 86 WHO grade 1 (low grade) meningiomas and 99 grade 2/3 (high grade) meningiomas. An oxidative stress-based molecular classification was developed in high-grade meningiomas through consensus clustering analysis. Immune microenvironment features, responses to immunotherapy and chemotherapy, and targeted drugs were evaluated. Three machine learning models: logistic regression, support vector machine, and random forest, were built for differentiating the classification. Key oxidative stress-related genes were verified in human meningeal cells (HMC) and two meningioma cells (CH-157MN and IOMM-Lee) via reverse transcription quantitative polymerase chain reaction (RT-qPCR) and western blot. After knockdown of Forkhead Box M1 (FOXM1) or Prion Protein (PRNP), cell growth, migration, and reactive oxygen species (ROS) levels were measured through cell counting kit-8 (CCK-8), transwell, and immunofluorescence, respectively.

Results: We classified high-grade meningiomas into two oxidative stress-based clusters, termed cluster 1 and cluster 2. Cluster 1 exhibited higher infiltrations of immune and stromal cells and higher expression of classic immune checkpoints: Cluster of Differentiation 86 (CD86), Programmed Cell Death 1 (PDCD1), and Leukocyte-Associated Immunoglobulin-Like Receptor 1 (LAIR1), indicating that cluster 1 meningiomas might respond to immunotherapy. Drug sensitivity was heterogeneous between the two clusters. Three classifiers were established, which could accurately differentiate this molecular classification. FOXM1 and PRNP were experimentally evidenced to be highly expressed in meningioma cells, and their knockdown hindered cell growth and migration and triggered ROS accumulation.

Conclusion: In summary, our findings established a novel oxidative stress-based molecular classification and identified potential treatment vulnerabilities in high-grade meningiomas, which might assist personalized clinical management.

WHO 2/3级脑膜瘤氧化应激分子分类及治疗脆弱性的研究
目的:世界卫生组织(WHO)基于组织病理学的分级不能总是准确预测脑膜瘤的肿瘤行为。为了克服WHO分级的局限性,本研究旨在提出一种新的基于氧化应激的WHO 2/3级脑膜瘤分子分级方法。方法:分析86例WHO 1级(低级别)脑膜瘤与99例WHO 2/3级(高级别)脑膜瘤之间氧化应激相关基因的差异表达。通过一致聚类分析,建立了基于氧化应激的高级别脑膜瘤分子分类。免疫微环境特征、对免疫治疗和化疗的反应以及靶向药物的评价。建立了逻辑回归、支持向量机和随机森林三种机器学习模型来区分分类。通过逆转录定量聚合酶链反应(RT-qPCR)和western blot方法,验证了人脑膜细胞(HMC)和两个脑膜瘤细胞(CH-157MN和IOMM-Lee)中氧化应激相关的关键基因。敲除叉头盒M1 (FOXM1)或朊蛋白(PRNP)后,分别通过细胞计数试剂盒-8 (CCK-8)、transwell和免疫荧光检测细胞生长、迁移和活性氧(ROS)水平。结果:我们将高级别脑膜瘤分为两个基于氧化应激的簇,称为簇1和簇2。簇1表现出更高的免疫细胞和基质细胞浸润以及经典免疫检查点:分化簇86 (CD86)、程序性细胞死亡1 (PDCD1)和白细胞相关免疫球蛋白样受体1 (LAIR1)的更高表达,表明簇1脑膜瘤可能对免疫治疗有反应。两组患者的药物敏感性存在异质性。建立了3个分类器,可以准确区分这种分子分类。实验证明FOXM1和PRNP在脑膜瘤细胞中高表达,敲低FOXM1和PRNP抑制细胞生长和迁移,引发ROS积累。结论:总之,我们的研究结果建立了一种新的基于氧化应激的分子分类,并确定了高级别脑膜瘤的潜在治疗漏洞,这可能有助于个性化的临床管理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Oncology Research
Oncology Research 医学-肿瘤学
CiteScore
4.40
自引率
0.00%
发文量
56
审稿时长
3 months
期刊介绍: Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信